SK282516B6 - Farmaceutický prípravok na liečenie pacientov s predĺženým časom zrážania krvi - Google Patents
Farmaceutický prípravok na liečenie pacientov s predĺženým časom zrážania krvi Download PDFInfo
- Publication number
- SK282516B6 SK282516B6 SK428-93A SK42893A SK282516B6 SK 282516 B6 SK282516 B6 SK 282516B6 SK 42893 A SK42893 A SK 42893A SK 282516 B6 SK282516 B6 SK 282516B6
- Authority
- SK
- Slovakia
- Prior art keywords
- epi
- coagulation
- plasma
- inhibitor
- time
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK261490A DK261490D0 (da) | 1990-10-31 | 1990-10-31 | New pharmaceutical compound |
| PCT/DK1991/000317 WO1992007584A1 (en) | 1990-10-31 | 1991-10-18 | Pharmaceutical preparation for the treatment of prolonged coagulation time |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK42893A3 SK42893A3 (en) | 1993-09-09 |
| SK282516B6 true SK282516B6 (sk) | 2002-10-08 |
Family
ID=8113744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK428-93A SK282516B6 (sk) | 1990-10-31 | 1991-10-18 | Farmaceutický prípravok na liečenie pacientov s predĺženým časom zrážania krvi |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0558529B1 (da) |
| JP (1) | JPH06502171A (da) |
| AT (1) | ATE132757T1 (da) |
| AU (1) | AU657926B2 (da) |
| CA (1) | CA2095356A1 (da) |
| CZ (1) | CZ282497B6 (da) |
| DE (1) | DE69116380T2 (da) |
| DK (2) | DK261490D0 (da) |
| ES (1) | ES2083597T3 (da) |
| GR (1) | GR3019514T3 (da) |
| HU (1) | HUT64236A (da) |
| RU (1) | RU2127600C1 (da) |
| SK (1) | SK282516B6 (da) |
| UA (1) | UA35567C2 (da) |
| WO (1) | WO1992007584A1 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030171292A1 (en) | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| AU636080B1 (en) * | 1992-07-21 | 1993-04-08 | Profy International Corporation | Unitary loose sheet binder |
| CA2406583A1 (en) * | 2000-05-10 | 2001-11-15 | Novo Nordisk A/S | Pharmaceutical composition comprising a factor viia and a factor xiii |
| US7015194B2 (en) | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| AU2002365131B2 (en) | 2001-10-15 | 2007-03-01 | Novartis Vaccines And Diagnostics, Inc. | Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI) |
| WO2007014749A2 (en) * | 2005-07-29 | 2007-02-08 | Universiteit Van Maastricht | Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor |
| EP2297203A1 (en) | 2008-06-30 | 2011-03-23 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| DK2379096T3 (da) | 2008-12-19 | 2019-11-25 | Baxalta GmbH | TFPI-inhibitorer og fremgangsmåder til anvendelse |
| US8450275B2 (en) | 2010-03-19 | 2013-05-28 | Baxter International Inc. | TFPI inhibitors and methods of use |
| PL2379600T5 (pl) * | 2008-12-22 | 2021-03-08 | Novo Nordisk A/S | Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego |
| US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
| RS61082B1 (sr) * | 2010-02-26 | 2020-12-31 | Novo Nordisk As | Stabilno antitelo koje sadrži kompozicije |
| EP2542257B1 (en) | 2010-03-01 | 2017-07-05 | Bayer Healthcare LLC | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| US9228022B2 (en) | 2010-06-30 | 2016-01-05 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| CN103080135B (zh) | 2010-06-30 | 2017-06-13 | 诺沃—诺迪斯克有限公司 | 能够特异性结合组织因子途径抑制剂的抗体 |
| HUE046572T2 (hu) | 2012-03-21 | 2020-03-30 | Baxalta GmbH | TFPI inhibitorok és alkalmazási eljárások |
| WO2014015133A1 (en) | 2012-07-19 | 2014-01-23 | National Cheng Kung University | Treatment of osteoarthritis using il-20 antagonists |
| US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
| US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL87172A (en) * | 1987-07-23 | 1994-12-29 | Univ Washington | A method of inhibiting the isolation of a purer tissue factor |
| IL87171A (en) * | 1987-11-23 | 1995-08-31 | Monsanto Co | ANDC of human tissue factor inhibitor |
| NZ228370A (en) | 1988-03-17 | 1994-01-26 | Novo Nordisk As | Heparin-binding protein and preparation thereof. |
| DK148890D0 (da) * | 1990-06-19 | 1990-06-19 | Novo Nordisk As | Farmaceutisk praeparat |
-
1990
- 1990-10-31 DK DK261490A patent/DK261490D0/da not_active Application Discontinuation
-
1991
- 1991-10-18 SK SK428-93A patent/SK282516B6/sk unknown
- 1991-10-18 AT AT91919614T patent/ATE132757T1/de not_active IP Right Cessation
- 1991-10-18 JP JP3518142A patent/JPH06502171A/ja active Pending
- 1991-10-18 CA CA002095356A patent/CA2095356A1/en not_active Abandoned
- 1991-10-18 DK DK91919614.7T patent/DK0558529T3/da active
- 1991-10-18 ES ES91919614T patent/ES2083597T3/es not_active Expired - Lifetime
- 1991-10-18 HU HU9301253A patent/HUT64236A/hu unknown
- 1991-10-18 EP EP91919614A patent/EP0558529B1/en not_active Expired - Lifetime
- 1991-10-18 AU AU88711/91A patent/AU657926B2/en not_active Ceased
- 1991-10-18 RU RU93032613A patent/RU2127600C1/ru active
- 1991-10-18 UA UA93004415A patent/UA35567C2/uk unknown
- 1991-10-18 CZ CZ93786A patent/CZ282497B6/cs not_active IP Right Cessation
- 1991-10-18 WO PCT/DK1991/000317 patent/WO1992007584A1/en active IP Right Grant
- 1991-10-18 DE DE69116380T patent/DE69116380T2/de not_active Expired - Fee Related
-
1996
- 1996-04-02 GR GR960400902T patent/GR3019514T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE132757T1 (de) | 1996-01-15 |
| WO1992007584A1 (en) | 1992-05-14 |
| DE69116380T2 (de) | 1996-07-11 |
| EP0558529B1 (en) | 1996-01-10 |
| UA35567C2 (uk) | 2001-04-16 |
| DE69116380D1 (de) | 1996-02-22 |
| DK261490D0 (da) | 1990-10-31 |
| RU2127600C1 (ru) | 1999-03-20 |
| HUT64236A (en) | 1993-12-28 |
| ES2083597T3 (es) | 1996-04-16 |
| DK0558529T3 (da) | 1996-06-03 |
| EP0558529A1 (en) | 1993-09-08 |
| CZ78693A3 (en) | 1993-12-15 |
| CA2095356A1 (en) | 1992-05-01 |
| AU8871191A (en) | 1992-05-26 |
| CZ282497B6 (cs) | 1997-07-16 |
| JPH06502171A (ja) | 1994-03-10 |
| AU657926B2 (en) | 1995-03-30 |
| HU9301253D0 (en) | 1993-07-28 |
| SK42893A3 (en) | 1993-09-09 |
| GR3019514T3 (en) | 1996-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK282516B6 (sk) | Farmaceutický prípravok na liečenie pacientov s predĺženým časom zrážania krvi | |
| JP4422781B2 (ja) | 血液凝固第ｖｉｉ因子を活性化するプロテアーゼ | |
| Rapaport | The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation | |
| Butenas et al. | Platelets and phospholipids in tissue factor-initiated thrombin generation | |
| Sandset et al. | Extrinsic pathway inhibitor—the key to feedback control of blood coagulation initiated by tissue thromboplastin | |
| Luchtman-Jones et al. | The current status of coagulation | |
| US6090570A (en) | Method for specifically detecting a coagulation factor V which has an increased stability toward activated protein C in the activated state | |
| Demoulin et al. | Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection | |
| EP0690991B1 (en) | Novel anticoagulant cofactor activity | |
| Rapaport | Blood coagulation and its alterations in hemorrhagic and thrombotic disorders. | |
| Welsch et al. | Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas | |
| EP0535129B1 (en) | An anticoagulant preparation | |
| US20210290738A1 (en) | Fx activation process and its use in the preparation of a fxa composition | |
| US5804181A (en) | Pharmaceutical preparation for the prevention and treatment of blood coagulation disorders | |
| US5187155A (en) | Anticoagulant peptides | |
| Berrettini et al. | A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum | |
| Hellstern | Composition of plasma | |
| US20120270789A1 (en) | Treatment of coagulopathy with hyperfibrinolysis | |
| US5863896A (en) | Evaluation of substances for altering and for increasing APC response | |
| Van den Besselaar et al. | Tissue factor-induced coagulation can be inhibited by aprotinin (Trasylol) | |
| Series | Factor VIII | |
| Zivelin | The individual importance of factors II, VII, IX and X for the antithrombotic effect of the vitamin K antagonist warfarin |